Skip to main content
. 2015 Mar 27;10(3):e0120511. doi: 10.1371/journal.pone.0120511

Table 4. Correlation between clinicopathological features and PAM pathway activation, PIK3CA mutation and PTEN loss.

PAM activation PIK3CA mutation PTEN loss
Items (146 cases) (39 cases) (98 cases)
N (%) P N (%) P N (%) P
Menopause
Yes 63(43.2%) 0.238 16(41.0%) 0.6 47(48.0%) 0.151
No 83(56.8%) 23(59.0%) 51(52.0%)
Tumor size (cm)
T1 (T≤2) 34(23.3%) 0.246 7(17.9%) 0.345 26(26.5%) 0.772
T2 (2<T≤5) 88(60.3%) 25(64.2%) 59(60.2%)
T3 or larger (T>5) 24(16.4%) 7(17.9%) 13(13.3%)
Lymph node involvement
Positive 82(56.2%) 0.906 23(59.0%) 0.487 51(52.0%) 0.376
Negative 64(43.8%) 16(41.0%) 47(48.0%)
Tumor grade
1 4(2.7%) 0.711 2(5.1%) 0.421 1(1.0%) 0.427
2 45(30.8%) 9(23.1%) 31(31.7%)
3 97(66.5%) 28(71.8%) 66(67.3%)
ER status
Positive 83(56.8%) 0.28 24(61.5%) 0.918 52(53.1%) 0.041
Negative 63(43.2%) 15(38.5%) 46(46.9%)
PR status
Positive 93(63.7%) 0.318 22(56.4%) 0.138 62(63.3%) 0.284
Negative 53(36.3%) 17(43.6%) 36(36.7%)
HER2 status
Positive 13(8.9%) 0.833 5(12.8%) 0.359 8(8.2%) 0.94
Negative 133(91.1%) 34(87.2%) 90(91.8%)
Unknown 0 0 0
Ki67 index
≥14% 107(73.3%) 0.438 32(82.1%) 0.174 74(75.5%) 0.269
<14% 39(26.7%) 7(17.9%) 24(24.5%)